Across 3 studies, all reported beneficial moderate-sized effects of Saccharomyces boulardii on reducing stool frequency in children with acute diarrhea. The most commonly studied dose was 250 mg twice daily, studied primarily in pediatric populations.
Studied populations: children with acute diarrhea
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). All studies focused on acute diarrhea in children; effects on chronic diarrhea or adult populations are not established.
Generated Jul 12, 2026
Doses used in studies
mg/day: 500 (median 500, IQR 500–500)— 1 study
Safety in these studies
Overall tolerabilityReported
this review and meta-analysis show that S. boulardii is safe